ArticleiScience2026
DPPA inhibits melanoma by targeting angiogenesis through activating autocrine IFN-γ-CXCL9/10/11-CXCR3 axis in vascular endothelial cells.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiangiogenic therapy has been considered an effective therapeutic approach for malignant melanoma (MM). The use of bevacizumab, an antiangiogenic agent for targeting VEGF, has been associated with a potentially high rate of side effects in the treatment of different types of tumors. Therefore, exploration of innovative antiangiogenic therapeutic agents may be useful for the treatment of MM. Dipalmitoylphosphatidic acid (DPPA), a biologically active phosphatidic acid, performs various biological functions in different cancers. Nevertheless, whether DPPA affects tumor development in MM has not been fully elucidated. In this study, we demonstrated that DPPA suppresses tumor growth and metastasis by significantly inhibiting tumor angiogenesis, but not cell proliferation and invasion of MM. DPPA inhibits tumor neovascularization might through regulating interferon γ (IFN-γ)-related signaling, which can further activate CXCL9/10/11-chemokine receptor 3 (CXCR3) signaling. Our findings suggest that DPPA has the potential to serve as an effective antiangiogenic agent for the treatment of MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.